Development of a leishmaniasis vaccine: the importance of MPL.

摘要: The parasite Leishmania has been used for pioneering work to define T-cell subsets and cytokine patterns mediating susceptibility or resistance infectious pathogens. This understanding essential the development of a new generation candidate vaccines major diseases, such as leishmaniases themselves, tuberculosis others. It is clear that effective can be developed through combination both antigen adjuvant selection. Until recently, no adjuvants acceptable use in human were available. However, one adjuvant, monophosphoryl lipid A, shown safe effective. Just responses necessary vaccines, an signaling by antigen-presenting cells A antigens at promoting durable T-helper 1 comprise promising vaccine candidate, Leish-111f. potential application prevention treatment leishmaniasis.